Simbrinza + Rocklatan for Open-Angle Glaucoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to explore how two medications, Simbrinza and Rocklatan, can help manage open-angle glaucoma, a common eye condition that can lead to vision loss. Researchers seek to determine if these drugs are more effective than the current standard treatment of Cosopt and Latanoprost. Individuals diagnosed with mild to moderate open-angle glaucoma who have used Cosopt and Latanoprost for at least a month might be suitable candidates for this trial. As a Phase 4 trial, this research helps to understand how these FDA-approved treatments can benefit more patients.
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop your current medications, but it requires participants to be on a combination of Cosopt and Latanoprost for at least 1 month before joining. It seems you may need to continue these medications during the trial.
What is the safety track record for Simbrinza and Rocklatan?
Research has shown that both Simbrinza and Rocklatan are generally safe for treating open-angle glaucoma. Studies have found that people with this eye condition usually tolerate these medications well. Simbrinza combines two drugs, brinzolamide and brimonidine tartrate, while Rocklatan contains netarsudil and latanoprost. Both effectively manage eye pressure.
Most people do well with these treatments, but some might experience mild side effects. For example, those with a history of eye inflammation should use Rocklatan with caution. Overall, both treatments are considered safe and have been used in glaucoma care for a long time.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about Simbrinza and Rocklatan for treating open-angle glaucoma because these medications target the condition in a unique way. Simbrinza combines brinzolamide and brimonidine tartrate, which work together to reduce eye pressure by decreasing fluid production and increasing drainage. Rocklatan, on the other hand, combines netarsudil and latanoprost, enhancing fluid outflow through different pathways. This dual-action approach is different from standard treatments like Cosopt and Latanoprost, which primarily focus on one mechanism. By using multiple mechanisms to lower eye pressure, Simbrinza and Rocklatan could offer more effective management of glaucoma symptoms.
What evidence suggests that Simbrinza and Rocklatan might be an effective treatment for open-angle glaucoma?
This trial will compare the effectiveness of Simbrinza and Rocklatan with Cosopt and Latanoprost for treating open-angle glaucoma (OAG). Research has shown that Simbrinza and Rocklatan effectively lower intraocular pressure. Specifically, studies found that Rocklatan, a combination of netarsudil and latanoprost, often reduces eye pressure more effectively than each drug alone. Simbrinza, which contains brinzolamide and brimonidine, also lowers eye pressure. These medications benefit patients requiring multiple drugs to control eye pressure. Both treatments are well-regarded for managing glaucoma symptoms by employing different methods to effectively reduce eye pressure.25678
Who Is on the Research Team?
Sandra Yeh, MD
Principal Investigator
Prairie Eye Center
Are You a Good Fit for This Trial?
Adults with mild to moderate open-angle glaucoma, who have been using Cosopt and Latanoprost for at least a month. Participants must have optic nerve damage, an intraocular pressure (IOP) between 18-28 mmHg, and corneal thickness of 450-650 µm. Excluded are those with recent eye surgeries or treatments, pregnant women, individuals on systemic medications affecting IOP, or with hypersensitivity to study drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Simbrinza and Rocklatan or Cosopt and Latanoprost for glaucoma treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Simbrinza and Rocklatan
Find a Clinic Near You
Who Is Running the Clinical Trial?
Prairie Eye Center
Lead Sponsor
Sengi
Industry Sponsor